Hadean Ventures logo

Hadean Ventures

Europe, Oslo, Norway, Oslo

Description

Hadean Ventures is a specialized life science fund manager based in Oslo, Norway, with a strategic focus on investing in innovative life science companies across Europe, particularly emphasizing the Nordic region. The firm manages funds with total commitments exceeding EUR 200 million, equivalent to over $216 million, underscoring its significant capital base dedicated to the sector. Their investment mandate covers a broad spectrum of life science innovations, including pharmaceuticals, medical devices, diagnostics, and digital health technologies, aiming to support the development of groundbreaking solutions that address critical healthcare needs.

The firm primarily targets companies raising their Series A or Series B funding rounds, indicating a preference for early to growth-stage ventures that have demonstrated initial traction or proof-of-concept. Hadean Ventures typically deploys initial investments ranging from EUR 3 million to EUR 10 million, which translates to approximately $3.24 million to $10.8 million. This range positions them as a key financial partner for companies seeking substantial capital to advance their research, development, and commercialization efforts. They also have the capacity to invest up to EUR 20 million over the lifetime of a portfolio company, demonstrating a commitment to long-term support.

Hadean Ventures distinguishes itself through its team's deep scientific and commercial expertise, which enables them to provide more than just capital. They actively engage with their portfolio companies, offering strategic guidance, operational support, and access to their extensive network within the life science industry. This hands-on approach is designed to accelerate the growth and success of their investments, fostering the development of companies that can make a significant impact on global health. Their strategic location in Norway further strengthens their access to the vibrant Nordic life science ecosystem, a region known for its strong research institutions and innovative startups.

Investor Profile

Hadean Ventures has backed more than 25 startups, with 1 new investments in the last 12 months alone. The firm has led 11 rounds, about 44% of its total and boasts 5 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series Unknown, Series B rounds (top funding stages).
  • Majority of deals are located in Sweden, Norway, Germany.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
  • Typical check size: $3.2M – $10.8M.

Stage Focus

  • Series A (36%)
  • Series Unknown (24%)
  • Series B (20%)
  • Series D (8%)
  • Series C (8%)
  • Post Ipo Equity (4%)

Country Focus

  • Sweden (32%)
  • Norway (16%)
  • Germany (12%)
  • Austria (8%)
  • United States (8%)
  • Denmark (4%)
  • The Netherlands (4%)
  • Finland (4%)
  • Spain (4%)
  • United Kingdom (4%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Biopharma
  • Therapeutics
  • Artificial Intelligence (Ai)
  • Software
  • Clinical Trials
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Hadean Ventures frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 2
OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Bristol-Myers Squibb
North America, New York, United States, New York
Co-Investments: 2
Canica
Europe, Oslo, Norway, Oslo
Co-Investments: 2
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 3
Fund+
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 2
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 2
Helicase Venture
North America, Massachusetts, United States, Boston
Co-Investments: 3
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 3
Sunstone Life Science Ventures
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 3

What are some of recent deals done by Hadean Ventures?

Actithera

Oslo, Oslo, Norway

Actithera is a molecular radiotherapeutic company that develops radioligand therapies.

BiotechnologyHealth CareLife ScienceMedicalTherapeutics
Series AJul 9, 2025
Amount Raised: $75,500,000
Gesynta Pharma

Stockholm, Stockholms Lan, Sweden

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

BiopharmaHealth CarePharmaceutical
Series BJan 20, 2025
Amount Raised: $27,270,688
SciRhom

Martinsried, Bayern, Germany

SciRhom is a biotech enterprise that translate advanced scientific findings into game-changing therapies for autoimmune diseases.

BiotechnologyHealth Care
Series AJul 9, 2024
Amount Raised: $68,190,674
ARTHEx Biotech

Valencia, Comunidad Valenciana, Spain

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Biotechnology
Series BMay 3, 2023
Amount Raised: $46,487,689
Complement Therapeutics

London, England, United Kingdom

Complement Therapeutics operates as a preclinical stage company.

BiotechnologyMedical
Series AApr 17, 2023
Amount Raised: $78,657,148
Alex Therapeutics

Stockholm, Stockholms Lan, Sweden

AI digital CBT therapeutic platform - changing habits, changing health

Artificial Intelligence (AI)Assistive TechnologyHealth CareMedicalPersonal HealthSoftwareTherapeutics
Series UnknownMar 3, 2023
Amount Raised: $5,054,713
Alex Therapeutics

Stockholm, Stockholms Lan, Sweden

AI digital CBT therapeutic platform - changing habits, changing health

Artificial Intelligence (AI)Assistive TechnologyHealth CareMedicalPersonal HealthSoftwareTherapeutics
Series UnknownApr 6, 2022
Amount Raised: $3,814,194
TargED Biopharmaceuticals

Utrecht, Utrecht, The Netherlands

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AFeb 19, 2022
Amount Raised: $44,156,009
Ribbon Biolabs

Vienna, Wien, Austria

Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.

Biotechnology
Series AJan 31, 2022
Amount Raised: $20,212,909
Emergence Therapeutics

Duisburg, Nordrhein-Westfalen, Germany

Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.

BiotechnologyFitnessHealth CareWellness
Series ADec 7, 2021
Amount Raised: $98,075,135